Clinical Trials
47 trialsNivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
GV20 Therapeutics
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
STARTRK-2
Hoffmann-La Roche
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
ANTARES
Instituto do Cancer do Estado de São Paulo
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
FORTITUDE-301
Amgen
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
KEYNOTE 158
Merck Sharp & Dohme LLC
KEYVIBE-005
Merck Sharp & Dohme LLC
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
ACROPOLI
SOLTI Breast Cancer Research Group
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
CVL009-C2001
Convalife (Shanghai) Co., Ltd.
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
MK-3475-E90
Wellmarker Bio
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
VUBAR
Universitair Ziekenhuis Brussel
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
ALpha-T
Hoffmann-La Roche
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
DUET-4
Xencor, Inc.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
DUET-2
Xencor, Inc.
A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
Wellmarker Bio
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Fore Biotherapeutics
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
iNSITE2
BIND Therapeutics